Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China.

Trial Profile

Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 17 Aug 2015 Planned primary completion date changed from 1 May 2013 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 17 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top